Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 378 participants.

Also called NCT01932112

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 378 participants (enrolled count) (from the registry)
Sponsor
Yong Seog Oh (from the registry)
Registry
  • NCT NCT01932112
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01932112. Allocation not applicable; no masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2015-04 (actual). Results posted on 2016-04-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)
Acronym
APPLE
Condition
Persistent Common Pulmonary Vein
Intervention (Drug)
Adenosine arm
Lead sponsor
Yong Seog Oh (class: other)

Record details

Record id
cardio:ct-nct01932112
Content hash
0e99e4f0febedfaf031f30f1b516db1c2ec1b0042b02ea0f41766bef299693b7